BioSpace News Archive

Aquarius Surgical Technologies Inc. released its financial results for the three-month, first-quarter-period ending June 30, 2021.

Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its CLIA/CAP certified lab Provista Diagnostics has successfully completed the validation studies required to put the Quidel Lyra Influenza A & B and the Lyra RSV & hMPV PCR kits into production alongside COVID PCR tests currently being run (together the “Provista Respiratory Panel”) and expects this new respiratory panel to be launched in September 2021

Canada’s largest pharmaceutical manufacturer, Apotex Inc., announced the Canadian launch of the generic version of Revlimid capsules, APO-lenalidomide for the treatment of multiple myeloma and Myelodysplastic syndrome.

Novanta Inc. (Nasdaq: NOVT) (the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Matthijs Glastra, Chairperson and Chief Executive Officer, and Robert Buckley, Chief Financial Officer, are scheduled to present at the Baird’s 2021 Global Healthcare Conference.

miR Scientific, LLC, a healthcare company focused on transforming global cancer management, the Governor of Puerto Rico, Pedro Pierluisi, and the Puerto Rico Health Insurance Administration (“ASES”) join forces today to officially make September 1 “Prostate Cancer Prevention Day”.

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the appointment of Steven Hamburger, Ph.D. as Senior Vice President of Regulatory Affairs and Quality Assurance.

X4 Pharmaceuticals, Inc. announced that, on August 31, 2021, the Compensation Committee of X4’s Board of Directors issued an inducement award to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan.

Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the first quarter of fiscal year 2022 on September 8, 2021

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, announced that on August 31, 2021, the Company granted restricted stock units to one new employee of the Company.

Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system, today announced that Foghorn management will participate in two upcoming virtual investor conferences.